China Meheco(SH:600056) Di Yi Cai Jing·2025-12-27 06:21Core Viewpoint - The investigation of Gao Yuwen, former chairman of China National Pharmaceutical Group, is linked to serious violations of discipline and law, and he is currently under disciplinary review and investigation by the Central Commission for Discipline Inspection and the National Supervisory Commission [1][3] Group 1: Company Background and Leadership Changes - Gao Yuwen resigned from his position as chairman of China National Pharmaceutical Group in February 2021 due to work adjustments and has not held any company positions since then [1] - China National Pharmaceutical Group, established in 1983, became part of the General Technology Group in 1999 and is now the sole platform for pharmaceuticals and medical devices under the group [1] Group 2: Internal Investigations and Corruption - Since 2024, at least 11 executives or former executives from China National Pharmaceutical Group and its subsidiaries have been investigated for serious violations of discipline and law [2] - Li Xin, former assistant to the general manager, is also under investigation, having retired in October 2022 but continuing to hold other positions within the company [2] - Multiple subsidiaries, including Hebei General Huachuang Medical Equipment Co., Ltd. and Hubei General Pharmaceutical Co., Ltd., have seen executives investigated, with Hubei General Pharmaceutical having the highest number of four individuals under investigation [2] Group 3: Financial Performance - In 2024, the company reported a revenue of 34.148 billion yuan, a year-on-year decrease of 12.04%, and a net profit attributable to shareholders of 535 million yuan, down 48.91% [4] - For the first half of 2025, the company achieved a revenue of 17.076 billion yuan, a decline of 6.71%, and a net profit of 294 million yuan, down 16.19% [4] - In the first three quarters of 2025, the net profit attributable to shareholders was 477 million yuan, reflecting a year-on-year decrease of 4.64% [4]